RxDoctor Payments DataLook up a doctor →

Aniel Navarro Marin, MD

Family Medicine · Miami, FLNPI 1750724621

Payments from drug & device makers

$7,311,083in general payments, 2019–2025

Across 805 payments — averaging $9082.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$3.2M
  • Janssen Research & Development, LLC$2.2M
  • Novartis$1M
  • Chiesi USA, Inc.$521K
  • Bausch Health US, LLC$401K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$29
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$52100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,311,083 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$122,401
Medicare patients
62
Services billed
1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$153,844
EliquisApixaban241$136,783
MounjaroTirzepatide59$68,222
JanuviaSitagliptin Phosphate91$53,507
JardianceEmpagliflozin65$40,396
XareltoRivaroxaban65$39,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$32,663
FarxigaDapagliflozin Propanediol57$32,408
LinzessLinaclotide53$28,073
Combivent RespimatIpratropium/Albuterol Sulfate51$24,909
BrilintaTicagrelor45$23,682
Tadalafil133$22,586
Breo ElliptaFluticasone/Vilanterol55$22,232
RestasisCyclosporine27$17,197
MupirocinMupirocin Calcium90$15,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,012,068$9,30814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →